Rituximab and mycophenolate mofetil may offer the most effective off-label alternatives for NMOSD patients, according to a study.| Neuromyelitis News
The platelet-to-lymphocyte ratio may be used as a biomarker of disability severity in people with NMOSD, a study found.| Neuromyelitis News
Margarida Maia is a science writer for Neuromyelitis News with a PhD in biomedical sciences. She covers the latest news and information on a variety of NMO topics.| Neuromyelitis News
NMOSD patients who are positive for the anti-AQP4 antibodies were more likely to have other autoimmune diseases, a study in Argentina shows.| Neuromyelitis News
A new predictive model to identify neuromyelitis optica spectrum disorder patients at a higher risk of relapse was found accurate in a study.| Neuromyelitis News
A Phase 1 clinical study tested the therapy in 15 patients positive for antibodies against AQP4, those most commonly associated with NMOSD.| Neuromyelitis News
Category archive page for News.| Neuromyelitis News